Vandetanib (ZD6474)

Cat. No.: OB0225WX-2812

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Vandetanib is a potent multi-kinase inhibitor that targets VEGFR2 (IC50: 40 nM), VEGFR3 (IC50: 110 nM), and EGFR (IC50: 500 nM) and is known to induce autophagy via ROS elevation.

Synonym: ZD6474; 443913-73-3; Vandetanib; Zactima; Caprelsa; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; ZD-6474; ZD 6474; GNF-PF-2188; ZD-64; NSC-744325; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; MFCD07772346; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine; 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-

CAS No.: 443913-73-3

Compound CID: 3081361

Formula: C₂₂H₂₄BrFN₄O₂

Formula Weight: 475.35

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Vandetanib is utilized in oncology research as a potent multi-kinase inhibitor targeting VEGFR, EGFR, and RET to investigate the simultaneous suppression of tumor-induced angiogenesis and growth factor signaling.